Targeted delivery of Chil3/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles

Choi, Mark; Jeong, Haeyoon; Kim, Sol; Kim, Minkyung; Lee, Minhyung; Rhim, Taiyoun

doi:10.1039/c9nr06382j

Cited by 23 publications

(16 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That is why experiments have been directed towards using nanoparticles for delivery of siRNAs in cancer therapy [ 72 , 73 , 74 , 75 ]. Polymeric nanoparticles [ 76 ], micelles [ 77 ], dendrimer [ 78 ], liposome [ 78 ], exosome [ 79 ], silicon-lipid nanoparticles [ 80 ] and cationic nanoemulsions [ 81 ] have been applied for delivery and controlled release of siRNA in cancer therapy. A recent experiment has used selenium nanostructures for delivery of Derlin1-siRNA in cervical cancer treatment.…”

Section: Sirnas: From Basic To Application In Cancer Therapymentioning

confidence: 99%

Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy

Mirzaei

Gholami

Ang

et al. 2021

Cells

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the leading causes of death and is the fourth most malignant tumor in men. The epigenetic and genetic alterations appear to be responsible for development of PC. Small interfering RNA (siRNA) is a powerful genetic tool that can bind to its target and reduces expression level of a specific gene. The various critical genes involved in PC progression can be effectively targeted using diverse siRNAs. Moreover, siRNAs can enhance efficacy of chemotherapy and radiotherapy in inhibiting PC progression. However, siRNAs suffer from different off target effects and their degradation by enzymes in serum can diminish their potential in gene silencing. Loading siRNAs on nanoparticles can effectively protect them against degradation and can inhibit off target actions by facilitating targeted delivery. This leads to enhanced efficacy of siRNAs in PC therapy. Moreover, different kinds of nanoparticles such as polymeric nanoparticles, lipid nanoparticles and metal nanostructures have been applied for optimal delivery of siRNAs that are discussed in this article. This review also reveals that how naked siRNAs and their delivery systems can be exploited in treatment of PC and as siRNAs are currently being applied in clinical trials, significant progress can be made by translating the current findings into the clinical settings.

show abstract

Section: Sirnas: From Basic To Application In Cancer Therapymentioning

confidence: 99%

Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy

Mirzaei

Gholami

Ang

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Efficient gene knockdown was also observed in lung tissues of healthy mice following pulmonary delivery [ 28 ] ( Table 1 ). Choi et al developed a peptide-based vector that comprises micelles of oligoarginine peptides as the siRNA carrier and high mobility group (HMG) peptide ligand that targets the activated alveolar macrophages, with promising biological effects in an asthma model [ 30 ] ( Table 1 ). Recently, Qiu et al developed KL4 peptide, a surfactant protein B mimic, for delivering both siRNA and mRNA to the lung with good transfection efficiency [ 25 , 31 ].…”

Section: Rna Delivery Vectors For Pulmonary Deliverymentioning

confidence: 99%

“…Despite the promising effect of pulmonary naked RNA delivery, the exact mechanism of how naked RNA crosses the cell membrane barrier in the lung remains unclear, although it has been suggested that the pulmonary surfactant has a significant role in facilitating RNA uptake [25,26]. Some studies also showed that the use of delivery vectors could significantly improve RNA transfection compared with naked RNA in the airways [27][28][29][30][31].…”

Section: Highlightsmentioning

confidence: 99%

“…Efficient gene knockdown was also observed in lung tissues of healthy mice following pulmonary delivery [28] (Table 1). Choi et al developed a peptide-based vector that comprises micelles of oligoarginine peptides as the siRNA carrier and high mobility group (HMG) peptide ligand that targets the activated alveolar macrophages, with promising biological effects in an asthma model [30] ( [ 25,31]. The PEGylated KL4 peptide was also used to formulate mRNA as inhalable dry powder by spray-drying and spray-freeze drying techniques, with efficient gene expression observed in the lung of healthy mice [31] (Table 1).…”

Section: Peptide-based Delivery Systemsmentioning

confidence: 99%

“…A PubMed search was performed using the search terms 'siRNA' or 'mRNA', 'pulmonary delivery', 'intratracheal', 'inhalation', 'nebulization', and with the filters 'last 5 years' (publication date) and 'other animals' (species) . In total, 53 articles were included in the survey [10][11][12][13][14][15][16][17][18][19][20][21][22][23][27][28][29][30][31]36,38,40,[45][46][47][48][50][51][52][53][60][61][62][63][64][65]67,69,[73][74][75][76][77][78][79][80][81][82][83][84]…”

Section: Lessons Learnt From These Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Inhaled RNA Therapy: From Promise to Reality

Chow

Qiu

Lam

2020

Trends in Pharmacological Sciences

View full text Add to dashboard Cite

RNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation remains identifying a safe and effective delivery system. Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure. In this review, we highlight recent developments in pulmonary RNA delivery systems with the use of nonviral vectors. We also discuss the major knowledge gaps that require thorough investigation and provide insights that will help advance this exciting field towards the bedside.

show abstract

The DNA binding high mobility group box protein family functionally binds RNA

et al. 2023

View full text Add to dashboard Cite

Nucleic acid binding proteins regulate transcription, splicing, RNA stability, RNA localization, and translation, together tailoring gene expression in response to stimuli. Upon discovery, these proteins are typically classified as either DNA or RNA binding as defined by their in vivo functions; however, recent evidence suggests dual DNA and RNA binding by many of these proteins. High mobility group box (HMGB) proteins have a DNA binding HMGB domain, act as transcription factors and chromatin remodeling proteins, and are increasingly understood to interact with RNA as means to regulate gene expression. Herein, multiple layers of evidence that the HMGB family are dual DNA and RNA binding proteins is comprehensively reviewed. For example, HMGB proteins directly interact with RNA in vitro and in vivo, are localized to RNP granules involved in RNA processing, and their protein interactors are enriched in RNA binding proteins involved in RNA metabolism. Importantly, in cell‐based systems, HMGB–RNA interactions facilitate protein–protein interactions, impact splicing outcomes, and modify HMGB protein genomic or cellular localization. Misregulation of these HMGB–RNA interactions are also likely involved in human disease. This review brings to light that as a family, HMGB proteins are likely to bind RNA which is essential to HMGB protein biology.This article is categorized under: RNA Interactions with Proteins and Other Molecules > Protein‐RNA Recognition RNA Interactions with Proteins and Other Molecules > RNA‐Protein Complexes RNA Interactions with Proteins and Other Molecules > Protein‐RNA Interactions: Functional Implications

show abstract

Targeted delivery of Chil3/Chil4 siRNA to alveolar macrophages using ternary complexes composed of HMG and oligoarginine micelles

Abstract: Cell-type-specific genes involved in disease can be effective therapeutic targets; therefore, the development of a cell-type-specific gene delivery system is essential.

Cited by 23 publications

References 47 publications

Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy

Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy

Inhaled RNA Therapy: From Promise to Reality

The DNA binding high mobility group box protein family functionally binds RNA

Contact Info

Product

Resources

About